Innate Pharma Has Dosed The First Patient In MATISSE Phase 2 Study Evaluating Neoadjuvant And Adjuvant Treatment With IPH5201 Plus Durvalumab And Chemotherapy, In Treatment-naïve Patients With Resectable Early Stage Non-small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma has dosed the first patient in the MATISSE Phase 2 study, evaluating neoadjuvant and adjuvant treatment with IPH5201 plus Durvalumab and chemotherapy for early-stage non-small cell lung cancer. Innate is responsible for conducting the study and shares costs with AstraZeneca, which supplies the clinical trial drugs.
June 26, 2023 | 7:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca partners with Innate Pharma for the MATISSE Phase 2 study, supplying clinical trial drugs for early-stage non-small cell lung cancer treatment.
AstraZeneca's partnership with Innate Pharma for the MATISSE Phase 2 study could potentially lead to a new treatment for early-stage non-small cell lung cancer. This collaboration may have a positive impact on AstraZeneca's stock price in the short term as it demonstrates the company's commitment to developing new treatments.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Innate Pharma has dosed the first patient in the MATISSE Phase 2 study for early-stage non-small cell lung cancer treatment, partnering with AstraZeneca.
Innate Pharma's initiation of the MATISSE Phase 2 study, in partnership with AstraZeneca, could potentially lead to a new treatment for early-stage non-small cell lung cancer. This development may have a positive impact on Innate Pharma's stock price in the short term as it demonstrates the company's progress in clinical trials and its collaboration with a major pharmaceutical company.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100